Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

732
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
732
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

820
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
820
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

4.4K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Malignant B cells expressing SIRPĪ± are highly proliferative and are associated with inferior clinical outcomes in B-cell non-Hodgkin lymphoma.

LeukemiaĀ·2026
Same author

POD24 is a novel determinant of prognosis in patients with Waldenstrƶm macroglobulinemia.

Blood advancesĀ·2026
Same author

Efficacy and Safety of Capivasertib (AZD5363), a Potent, Oral Pan-AKT Inhibitor, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL).

Clinical cancer research : an official journal of the American Association for Cancer ResearchĀ·2025
Same author

Multi-omics analysis reveals a unique epigenetic signature in <i>MYD88</i> wild-type Waldenstrƶm macroglobulinemia.

HaematologicaĀ·2025
Same author

Unraveling lymphoma-induced immune senescence.

Cancer cellĀ·2025
Same author

Subsets of follicular lymphoma 3B have divergent outcomes: results from the prospective multicenter MER and LEO cohorts.

Blood cancer journalĀ·2025

Related Experiment Video

Updated: Apr 17, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

12.9K

Emerging drugs for diffuse large B-cell lymphoma.

Patrizia Mondello1, Anas Younes

  • 1Department of Human Pathology, University of Messina, Via C. Valeria, 98100 Messina, Italy.

Expert Review of Anticancer Therapy
|February 6, 2015
PubMed
Summary
This summary is machine-generated.

Diffuse large B-cell lymphoma (DLBCL) remains a challenge, with many patients not responding to current treatments. Emerging targeted therapies show promise for a personalized approach to improve outcomes for DLBCL patients.

Keywords:
Bcl-2DLBCLHDACMYCPI3Kbromodomainibrutiniblenalidomidemonoclonal antibodies

More Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

4.0K
Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

1.0K

Related Experiment Videos

Last Updated: Apr 17, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

12.9K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

4.0K
Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

1.0K

Area of Science:

  • Oncology
  • Hematology
  • Genetics

Background:

  • Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma in Western countries.
  • Current first-line treatments including rituximab combined with chemotherapy have limitations, with nearly one-third of patients experiencing treatment failure or relapse.
  • Gene expression profiling has identified distinct DLBCL subgroups with unique biological features and treatment responses.

Purpose of the Study:

  • To review emerging therapeutic strategies for DLBCL.
  • To focus on novel agents targeting specific DLBCL molecular subsets.
  • To discuss findings from preclinical and early clinical trials and outline future research directions.

Main Methods:

  • Literature review of preclinical studies and early-phase clinical trials.
  • Analysis of gene expression profiling data to identify DLBCL subgroups.
  • Discussion of novel therapeutic agents and their mechanisms of action.

Main Results:

  • Identification of three main DLBCL molecular signatures associated with differential prognoses.
  • Emerging targeted therapies are being investigated to address the oncogenic drivers within these subsets.
  • Early data suggests potential for tailored treatment approaches to improve efficacy and reduce toxicity.

Conclusions:

  • Novel agents targeting specific DLBCL molecular drivers offer a promising avenue for personalized medicine.
  • Further investigation in clinical trials is crucial to validate the efficacy and safety of these emerging therapies.
  • A tailored therapeutic strategy holds the potential to improve outcomes for patients with refractory or relapsed DLBCL.